Laboratory research efforts of our faculty are directed at both epithelial and hematologic malignancies, as well as benign hematologic diseases. Individual research faculty have joint appointments in the Center for Cancer Research, the Center for Regenerative Medicine, as well as active collaborations with relevant clinical disease centers within the Mass General Cancer Center.
Our Hematology & Medical Oncology Investigators are:
- Leif W. Ellisen, MD, PhD
- Jeffrey A. Engelman, MD, PhD
- Daniel A. Haber, MD, PhD
- Hanno Hock, MD, PhD
- Othon Iliopoulos, MD
- David J. Kuter, DPhil, MD
- Elizabeth B. Lamont, MD, MS
- Noopur Raje, MD
- Sridhar Ramaswamy, MD
- Jeffrey G. Supko, PhD
About Cancer Research at the Massachusetts General Hospital Cancer Center
Massachusetts General Hospital was established in 1811 and is the original and largest teaching hospital of Harvard Medical School. With an annual budget of more than $500 million, it conducts the largest hospital-based research program in the United States, through major research centers in cancer, human genetics, regenerative biology, systems biology, AIDS, cardiovascular medicine, computational biology, cutaneous biology, transplantation biology and photomedicine.
Research on cancer -- ranging from studies of genetic and epigenetic causes to sophisticated imaging, molecular therapeutics, bioengineering and computational biology, and population-based prevention studies -- takes place across the entire institution: in the dedicated laboratories of the Center for Cancer Research, the Steele Laboratory within the department of radiation oncology, and in laboratories within the departments of medicine, surgery, radiation therapy, pediatrics, pathology, radiology, neurology, neurosurgery, molecular biology, orthopedics, urology, dermatology and psychiatry. Clinical research is orchestrated within dedicated multidisciplinary disease centers and supported by a centralized protocol office. Massachusetts General is proud of its exceptionally diverse and collaborative research program on cancer, spanning from the laboratory to the clinic.